Antiplatelet therapy and the risk of intracranial hemorrhage after intravenous tissue plasminogen activator therapy for acute ischemic stroke

Arch Neurol. 2008 May;65(5):575-6. doi: 10.1001/archneur.65.5.575.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Brain Ischemia / drug therapy*
  • Brain Ischemia / physiopathology
  • Cerebral Arteries / drug effects
  • Cerebral Arteries / pathology
  • Cerebral Arteries / physiopathology
  • Cerebral Hemorrhage / chemically induced*
  • Cerebral Hemorrhage / physiopathology
  • Cerebral Hemorrhage / prevention & control*
  • Clinical Trials as Topic / statistics & numerical data
  • Drug Interactions
  • Drug Synergism
  • Drug Therapy, Combination
  • Fibrinolytic Agents / adverse effects
  • Humans
  • Platelet Aggregation Inhibitors / adverse effects*
  • Risk Assessment
  • Secondary Prevention
  • Stroke / drug therapy*
  • Stroke / pathology
  • Stroke / physiopathology
  • Tissue Plasminogen Activator / adverse effects*

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • Tissue Plasminogen Activator